Form 4: AtriCure Executive Justin J. Noznesky Sells 1,500 Shares Under 10b5-1 Trading Plan

AtriCure's Chief Marketing & Strategy Officer, Justin J. Noznesky, sold 1,500 shares of common stock at $36.72 per share on March 12, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 12, 2024, Justin J. Noznesky, Chief Marketing & Strategy Officer of AtriCure, Inc. (ATRC), sold 1,500 shares of the company's common stock.
• The sale was executed at a price of $36.72 per share.
• This transaction was conducted under a 10b5-1 trading plan adopted on December 12, 2023.
• Following the reported transaction, Noznesky directly owns 74,284 shares of AtriCure common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to an insider stock sale under a pre-arranged plan. It doesn't convey any particularly positive or negative sentiment about the company's performance or prospects.

Industry Context

Insider sales are a common occurrence, and the use of a 10b5-1 trading plan suggests the sale was pre-planned and not based on any specific non-public information. Investors often monitor insider transactions for signals about a company's prospects, but sales under 10b5-1 plans are generally viewed as less informative than discretionary trades.

Comparison to Industry Standards

• Comparing AtriCure to similar medical device companies like Medtronic or Boston Scientific, insider trading activity is a common occurrence.
• The volume of shares sold is relatively small compared to the total outstanding shares of AtriCure.
• The use of a 10b5-1 plan is a standard practice among executives to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by an executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates